Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2016-09-01 Capital/Financing Update
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 1, 2016, by Titan Pharmaceuticals, Inc. The key content is the announcement of entering into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. This agreement allows the company to sell shares of common stock up to $20 million through an 'at the market offering.' The document includes details about the sales agreement, commission, and legal opinions but does not contain financial statements or detailed financial performance data. The primary purpose is to update on a financing activity, specifically a capital raising arrangement. Therefore, this filing fits the category of Capital/Financing Update (CAP). The document length is about 5,048 characters, which is sufficient to be the actual filing, not just an announcement of a report. Hence, the classification is CAP with high confidence.
2016-09-01 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 31, 2016. It specifically mentions that Titan Pharmaceuticals will present and post an updated corporate presentation on its website, and the presentation is attached as Exhibit 99.1. The document states that the information is furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not filed for purposes of Section 18 of the Securities Exchange Act. The key content is the announcement of a corporate presentation, not the presentation itself or detailed financial data. The document length is 2848 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Investor Presentation (IP) announcement within an 8-K filing, but since the actual presentation is attached as an exhibit and the document is primarily about the presentation, the classification aligns with Investor Presentation (IP).
2016-08-31 English
FORM 10-Q
Interim / Quarterly Report Q2 2016
2016-08-09 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 2, 2016. It reports on the departure and election of directors, results of shareholder votes at the Annual Meeting, and approval of amendments to the equity incentive plan. The key sections are Item 5.02 (Departure and Election of Directors) and Item 5.07 (Submission of Matters to a Vote of Security Holders). The document primarily announces changes in the board and voting results from the Annual Meeting. It is not a full annual report, audit report, or earnings release. The presence of director changes and voting results points to classification as either Board/Management Information (MANG) or Declaration of Voting Results & Voting Rights Announcements (DVA). Since the document includes detailed voting results and election outcomes, it fits best under Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4535 characters, which is sufficient to include substantive voting results rather than just an announcement of a report. Therefore, the classification is DVA with high confidence.
2016-08-03 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-07-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-07-19 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.